SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $218,730,000 | +66.0% | 1,375,229 | 0.0% | 5.50% | +30.3% |
| Q4 2018 | $131,733,000 | -13.0% | 1,375,229 | +28.4% | 4.22% | +5.4% |
| Q3 2018 | $151,331,000 | -9.8% | 1,071,373 | 0.0% | 4.00% | -17.3% |
| Q2 2018 | $167,702,000 | +3.9% | 1,071,373 | +6.9% | 4.84% | +8.5% |
| Q1 2018 | $161,463,000 | -6.0% | 1,002,439 | -3.8% | 4.46% | -7.7% |
| Q4 2017 | $171,700,000 | +152.3% | 1,042,439 | -4.6% | 4.84% | +156.6% |
| Q3 2017 | $68,059,000 | -5.8% | 1,092,439 | +20.4% | 1.88% | -14.7% |
| Q2 2017 | $72,268,000 | +4.6% | 907,439 | -6.7% | 2.21% | -2.3% |
| Q1 2017 | $69,111,000 | +32.4% | 972,439 | -4.9% | 2.26% | +16.9% |
| Q4 2016 | $52,206,000 | +10.9% | 1,022,439 | 0.0% | 1.93% | +16.9% |
| Q3 2016 | $47,083,000 | +83.7% | 1,022,439 | +20.2% | 1.66% | +63.5% |
| Q2 2016 | $25,630,000 | -4.1% | 850,639 | +2.0% | 1.01% | -4.7% |
| Q1 2016 | $26,727,000 | -35.3% | 833,663 | +17.6% | 1.06% | -8.8% |
| Q4 2015 | $41,315,000 | – | 708,663 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |